Terfenadine and placebo compared in the treatment of chronic idiopathic urticaria: a randomised double-blind study.

Terfenadine, a potent and non-sedative antihistamine, was shown to be effective in chronic idiopathic urticaria in a double-blind crossover placebo controlled trial. An oral twice daily 60 mg dose of terfenadine was given and itch and wheal parameters were assessed daily. Despite the overall effectiveness of terfenadine, a variable response was noted which was similar to that shown in previous studies with other antihistamines.

[1]  R. Cerio,et al.  Treatment of chronic idiopathic urticaria with terfenadine , 1984, Clinical allergy.

[2]  B. Stone,et al.  Performance studies with the H1-histamine receptor antagonists, astemizole and terfenadine. , 1982, British journal of clinical pharmacology.

[3]  J. Kalbfleisch,et al.  Combined H1 and H2 antihistamine therapy in chronic urticaria. , 1981, Archives of dermatology.

[4]  A. Kaplan.  The pathogenic basis of urticaria and angioedema: recent advances. , 1981, The American journal of medicine.

[5]  A. Kaplan,et al.  Assessment of tissue fluid histamine levels in patients with urticaria. , 1978, The Journal of allergy and clinical immunology.

[6]  R. Champion,et al.  URTICARIA AND ANGIO‐OEDEMA , 1969, The British journal of dermatology.

[7]  Wood Jk,et al.  Terfenadine, the first non-sedating antihistamine. , 1982 .

[8]  J. K. Woodward,et al.  Terfenadine, the first non-sedating antihistamine. , 1982, Arzneimittel-Forschung.